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Key Messages
 It is unclear whether systolic blood pressure level impacts cardiovascular disease inpatient costs and could be altered by peer
support in people with diabetes.
 The association between systolic blood pressure and cardiovascular disease inpatient payment showed a “hockey-stick” shapewith a
threshold at 133 to 141 mmHg.
 A novel 2-part model revealed that combined peer-support intervention altered this association.
a r t i c l e i n f o
Article history:
Received 13 February 2020
Received in revised form
8 June 2020
Accepted 31 July 2020
Keywords:
2-part model
health payment
hospitalization
systolic blood pressure
a b s t r a c t
Objectives: People with type 2 diabetes and increased systolic blood pressure (SBP) are at high risk of
cardiovascular disease (CVD). In this study, we aimed to investigate the association between CVD-related
hospital payments and SBP and tested whether this association is influenced by diabetes peer support.
Methods: Two cohorts comprising people with type 2 diabetes were included in the study. The first
cohort comprised 4,704 patients with type 2 diabetes assessed between 2008 and 2009 from 18 general
practices in Cambridgeshire and followed up to 2009e2011. The second cohort comprised 1,121 patients
with type 2 diabetes from post-trial follow-up data, recruited between 2011 and 2012 and followed up to
2015. SBP was measured at baseline. Inpatient payments for CVD hospitalization within 2 years since
baseline was the main outcome. The impact of 1:1, group or combined diabetes peer support and usual
care were investigated in the second cohort. Adjusted mean CVD inpatient payments per person were
estimated using a 2-part model after adjusting for baseline characteristics.
Results: A “hockey-stick” relationship between baseline SBP and estimated CVD inpatient payment was
identified in both cohorts, with a threshold at 133 to 141 mmHg, suggesting increased payments for
patients with SBP below and above the threshold. The combined peer-support intervention altered the
aforementioned association, with no increased payment with SBP above the threshold, and payment
slightly decreased with SBP beyond the threshold.
Conclusions: SBP maintained between 133 and 141 mmHg is associated with the lowest CVD disease
management costs for patients with type 2 diabetes. Combined peer-support intervention could
significantly decrease CVD-related hospital payments.
 2020 The Author(s). Published by Elsevier Inc. on behalf of Canadian Diabetes Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Objectifs : Les personnes ayant le diabète de type 2 et une augmentation de la pression artérielle sys-
tolique (PAS) sont exposées à un risque élevé de maladies cardiovasculaires (MCV). Dans la présente
étude, nous avions pour objectif d’examiner l’association entre les paiements des frais d’hospitalisation
liés à la MCV et la PAS, et de vérifier si l’entraide entre pairs diabétiques influence cette association.
Méthodes : Nous avons inclus à l’étude 2 cohortes de personnes atteintes du diabète de type 2. La pre-
mière cohorte regroupait 4704 patients atteints du diabète de type 2 de 18 cabinets de généralistes de
Cambridgeshire qui avaient été évalués entre 2008 et 2009 et suivis jusqu’en 2009e2011. La deuxième
cohorte regroupait 1121 patients atteints du diabète de type 2 qui avaient été recrutés entre 2011 et 2012
et suivis jusqu’en 2015 et dont les renseignements provenaient des données du suivi post-étude. Nous
avons mesuré la PAS au début. Les paiements des frais d’hospitalisation liés à la MCV dans les 2 ans
depuis le début étaient le critère principal d’évaluation. Nous avons examiné les répercussions de l’en-
traide entre pairs diabétiques 1:1, combinée ou en groupe et les soins courants de la seconde cohorte.
Nous avons estimé à l’aide d’un modèle en 2 parties les paiements moyens ajustés des frais d’hospi-
talisation liés à la MCV par personne après l’ajustement des caractéristiques initiales.
Résultats : Nous avons établi une relation en «bâton de hockey » entre la PAS initiale et le paiement
estimé des frais d’hospitalisation liés à la MCV dans les 2 cohortes, selon un seuil de 133 à 141 mmHg,
c’est-à-dire à une hausse des paiements chez les patients ayant une PAS sous et au-dessus du seuil.
L’intervention combinée de l’entraide entre pairs a modifié l’association mentionnée plus haut, soit
aucune augmentation de paiement lors de PAS au-dessus du seuil et une légère diminution de paiement
lors de PAS au-delà du seuil.
Conclusions : La PAS maintenue entre 133 et 141 mmHg est associée aux coûts de prise en charge des
MCV les plus faibles chez les patients atteints de diabète de type 2. L’intervention combinée de l’entraide
entre pairs pourrait diminuer de façon significative les paiements des frais d’hospitalisation liés à la MCV.
 2020 The Author(s). Published by Elsevier Inc. on behalf of Canadian Diabetes Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The rapid increase in prevalence and health costs associated
with type 2 diabetes has been observed worldwide (1). It has been
estimated that the risk of hospitalization is 2-fold higher in people
with diabetes vs those without diabetes, and the proportion with
diabetes is >10% in those admitted to hospital at any one time (2).
Among some specific age strata, this proportion is >20% (3). The
associated costs of excess admissions, as well as increased costs per
admission, are significant contributors to the financial burden
borne by health-care systems from diabetes and often reflect pre-
ventable morbidity suffered by patients (4). Systolic blood pressure
(SBP), as themost commonmodifiable risk factor, has been found to
be associated both with cardiovascular disease (CVD) mortality and
CVD hospitalization among people with type 2 diabetes (5,6).
However, no established association between SBP and inpatient
cost due to CVD hospitalization has been shown among people
with type 2 diabetes. Although a target SBP has been agreed upon
to lower the risk of, for example, CVD mortality and CVD hospi-
talization, it is unclear whether this threshold has an impact on
inpatient costs due to CVD mortality.
Diabetes peer support involves people with diabetes assisting
each other to improve their social, mental and physical well-being.
Peer support can be provided through individual or group
approaches and by either face-to-face or telephone or online con-
tact. It is generally seen as a low-cost intervention and has been
suggested to reduce health-care costs (7). Some studies have
reported that peer support can reduce health-care costs among
people with type 2 diabetes (8,9). The RAndomised controlled trial
of Peer Support In type 2 Diabetes (RAPSID) was the largest ran-
domized, controlled trial (RCT) of type 2 diabetes peer support to
date (10). The intervention was recently shown to be cost-effective
during the trial based on self-reported costs (11) and also from
prospective hospital costs (12). In RAPSID, group peer support was
associated with 2- to 3-mmHg lower SBP; however, it was unclear
whether this was amediator of the reduction in inpatient costs, and
whether this was through an effect on CVD hospitalization
specifically.
In this study, we investigated the association between SBP
measured in primary care settings and inpatient cost for CVD
hospitalization over the next 2 years, accounting for the risk of
hospitalization among people with type 2 diabetes, using data from
2 cohorts. We then examined the impact of peer support on this
association.
Methods
Data source and study population
We followed the methods of Yu et al for data and data collection
(12). Briefly, we utilized 2 cohorts from Cambridgeshire, England:
one (main cohort) based on the electronic health record data from
primary care settings to develop our CVD hospitalization and
rehospitalization risk scores, and another (replication cohort)
based on post-trial cohort data for external validation.
Main cohort
Patient lists from 18 general practices across Cambridgeshire,
England, in 2008e2009 were collated and linked with hospital
admissions (Secondary Uses Service) data as part of an evaluation
of diabetes care across the county by the local health board, the
National Health Service (NHS) Cambridgeshire. This cohort was
limited to volunteer practices using the Egton Medical Information
Systems general practitioner software system, from which a pre-
defined set of data could be extracted. There was no systematic
selection process for these surgeries, and data extracted were for
their entire diabetes population. All patients with diabetes had
follow-up hospitalization data to 2010e2011. Hospital admissions
to the NHS and private hospitals within and outside Cambridge-
shire were followed up. No personal identifiers were released to
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researchers, and all subsequent analyses were conducted on ano-
nymized data sets. Baseline blood pressure and clinical measure-
ments were recorded as part of clinical practice in primary care
settings (6).
Replication cohort
The design and methods of the RAPSID have been published
previously (10), including its Consolidated Standards of Reporting
Trials diagram and the results of its primary outcomes (10). Briefly,
RAPSID was a 22 factorial cluster RCT comparing 4 groups: con-
trols, 1:1 (individual) peer support, group peer support and com-
bined 1:1 and group peer support among patients with type 2
diabetes. Participants had their diabetes for at least 12 months and
those with dementia or mental illness were excluded. Participants
were recruited from communities across Cambridgeshire and
neighbouring areas of Essex and Hertfordshire. Follow-up data
were only available for participants in Cambridgeshire and neigh-
bouring areas of Hertfordshire that are served by the Cambridge-
shire and Peterborough Clinical Commissioning Group (CCG).
Clusters were defined by local government (parish council)
boundaries. The intervention was developed following a pilot,
using a framework defined by Peers for Progress (11). Peers facili-
tating peer support were termed peer-support facilitators and their
selection, training, support and the overall program have been
described elsewhere (10). The intervention lasted 8 to 12 months
and was commenced and concluded, cluster by cluster, between
June 2, 2011 to April 12, 2012.
Demographics, blood pressure, glycated hemoglobin (A1C) and
lipid profile information were collected at baseline. Blood pressure
was measured using an Omron electronic blood pressure monitor
(Model 705IT, Omron Corp, Kyoto, Japan) (13). Each participant was
followed up until June 2015 (0.91 to 4.07 years of follow up from
beginning/entry into the trial). Hospitalization (NHS hospitals and
private hospitals), accident and emergency and outpatient visits
within/outside Cambridgeshire and the included areas of Hertford-
shire were collected through the Cambridgeshire and Peterborough
CCG (14) as well as elective/nonelective status and International
Classification of Diseasesd10th revision (ICD-10) codes (6).
Ethics approval
Ethics approval was received from the Cambridgeshire REC2
Committee (10/H0308/72), and signed consent included agreement
for access to hospital data.
Defining CVD hospitalization
The primary outcome of the study was having at least 1 hospi-
talization with CVD as the primary diagnosis (ICD-10 codes I20 to
I25, I60 to I69 and I73 in the first ICD field) over the 2-year follow-
up period.
Statistical analysis
A large proportion of the diabetes population do not attend
hospital as an inpatient or outpatient in any given year and,
therefore, health-care payment data demonstrate a skewed utili-
zation/payment pattern (15). To take into account the problem of
“zero mass” and skewed outcomes, the demand functions were
modelled using a 2-part model (16). In this 2-part model, a probit
model was estimated for the probability of observing “zero” vs
positive medical expenditure. Positive medical expenditure is
defined as any health-care expenditure greater than zero. A
generalized linear model was estimated, conditional on having
health-care expenditure. The generalized linear model was used
instead of log ordinary least-squares regression, because it relaxes
the normality and homoscedasticity assumption and avoids bias
associated with retransforming to the raw scale (17). The results of
themodified Park test verified that the use of a gamma distribution,
with a log link, was the best-fitted generalized linear model for
consistent estimation of coefficients (18). The variance inflation
factor for all predictors used in the 2-part model indicated no
presence of multicollinearity (19). The F-test result for the 2-part
regression models was found to be significant, which indicated
the overall significance of the regression model. Predicted inpatient
cost was estimated in the 2-part model by the level of baseline SBP
with adjustment of other covariables. The 95% confidence intervals
for estimated payments were estimated by a bootstrap process
with 1,000 samples. Analysis restricted analyses in each financial
year were carried out as sensitivity analyses. All analyses were
performed with STATA version 14.0 (StataCorp, College Station,
Texas, United States).
Results
In our main cohort, we analyzed information on 4,704 type 2
diabetes patients with 588 CVD hospitalizations within 2 years. Our
replication cohort had information on 1,121 type 2 diabetes
patients with 183 CVD hospitalizations. Table 1 summarizes the
basic characteristics and clinical measurements of the study pop-
ulation. Patients with type 2 diabetes in both cohorts had similar
age, gender, blood pressure and total cholesterol. Patients in the
Table 1
Baseline characteristics of study cohorts
Main cohort Replication cohort
All Control 1:1 Group Combined
N 4,702 1,121 291 261 288 281
CVD hospitalization, n (%) 588 (12.5) 183 (16.3) 59 (20.3) 45 (17.2) 42 (14.6) 37 (13.2)
Age, years 65.016.3 65.511.4 65.912.8 65.39.8 65.811.9 65.010.4
Female, n (%) 1,919 (40.8) 444 (39.6) 122 (41.9) 109 (41.8) 101 (35.1) 112 (39.9)
Systolic blood pressure, mmHg 134.516.0 139.720.2 140.020.6 140.420.6 140.819.5 137.920.3
Diastolic blood pressure, mmHg 76.310.0 75.511.5 75.011.6 75.810.9 75.111.3 75.611.9
Total cholesterol, mmol/L 4.31.2 4.21.7 4.31.5 4.31.3 4.12.0 4.31.7
High-density lipoprotein, mmol/L 1.30.6 1.11.2 1.20.9 1.21.0 1.01.5 1.11.1
Low-density lipoprotein, mmol/L 2.51.4 1.43.0 1.33.2 1.52.8 1.52.8 1.53.0
Body mass index, kg/m2 30.86.9 32.26.0 32.36.0 32.66.5 32.05.9 32.25.9
A1C, mmol/mol 61.517.2 56.215.1 55.616.2 56.515.0 57.314.7 55.313.8
Lipid-lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 180 (61.9) 173 (66.3) 191 (66.3) 187 (66.6)
A1C, glycated hemoglobin; CVD, cardiovascular disease.
Note: Data expressed as number, number (%) or mean  standard deviation.
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main cohort had a higher level of high-density lipoprotein, low-
density lipoprotein and A1C. Compared with the main cohort,
those in the replication cohort were more likely to be prescribed
lipid-lowering medications. Baseline data for the 4 groups of the
replication cohort were well matched (Table 1). The sample size
of the main cohort and intervention groups of the replication
cohort, characteristics of participants and median cost in 2
cohorts by baseline SBP categories (<120, 120 to 129, 130 to 139,
140 to 149, 150 to 159 and >160 mmHg) are presented in Table 2.
As shown in Supplementary Table 1, inpatient cost data from
CVD hospitalization were typically skewed due to the mass of
“zero” payments and a relatively small proportion of patients
incurring extremely high expenditure. Of the participants in the
main and replication cohort, 87.5% and 83.7%, respectively, were
not hospitalized due to CVD diseases over the 2-year of follow up.
Within the replication cohort, 79.7% of controls and 82.8%, 85.4%
and 86.8% of patients in the 1:1 group and combined intervention
groups, respectively, were not hospitalized due to CVD disease.
Among patients hospitalized due to CVD diseases, median inpa-
tient costs were £4348.35 (interquartile range [IQR]: 1,623.50 to
8,766.75) and £2,430.72 (IQR: 793.06 to 4,026.20) for the main
and replication cohorts, respectively. With the replication cohort,
median inpatient costs were £2,419.60 (IQR: 1,006.91 to 4,387.66),
£2,489.40 (IQR: 770.69 to 4,387.66), £1,963.56 (IQR: 714.93 to
4,032.55) and £2,436.00 (IQR: 885.19 to 3,473.12) for the controls,
1:1 group and combined intervention groups, respectively.
Compared with patients without inpatient costs due to CVD
hospitalization, patients with such costs were more likely to be
older; male; have higher SBP, body mass index and A1C; and less
likely to have been prescribed lipid-lowering treatment
(Supplementary Table 2).
Results from 2-part model
Doseeresponse relationship curves between SBP and pre-
dicted inpatient cost for CVD hospitalization derived from the
2-part models after accounting for the risk of CVD hospitalization
with adjustment of covariables in Table 1 are presented in
Figure 1 for the main cohort and the replication cohort. SBP was
nonlinearly associated with adjusted predicted inpatient cost for
CVD hospitalization (linearity test: p<0.00001 for all) in both the
main and replication cohorts. The threshold was estimated at 137
(133 to 141) mmHg for SBP in both the main sample and repli-
cation sample, with consistent stable adjusted predicted inpatient
cost for CVD hospitalization below the threshold and increased
predicted inpatient cost above the threshold.
Within the replication cohort, doseeresponse relationship
curves between SBP and adjusted predicted inpatient cost for CVD
hospitalization in each group are presented in Figure 2. A
nonlinear association between SBP and adjusted predicted inpa-
tient cost was found in the control, 1:1 and intervention groups
(linearity test: p<0.00001 for all). The threshold at 137 (133 to
141) mmHg for SBP was found consistently in each group, with
consistent stable adjusted predicted inpatient cost for CVD hos-
pitalization below the threshold and increased predicted inpa-
tient cost above the threshold. In the combined intervention
group, the adjusted predicted inpatient cost was linearly stable as
SBP increased (linearity test: p¼0.05263). Associations between
baseline systolic blood pressure and predicted inpatient cost due
to CVD hospitalization in those receiving 1:1 peer support and
among the others within the replication cohort are presented in
Supplementary Figure 1. For each baseline SBP level, patients who
received the 1:1 peer-support intervention (as 1:1 alone or as the
combined intervention) were more likely to have lower inpatient
costs due to CVD hospitalization.Ta
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Discussion
In this study, using 2 prospective cohorts, we found a nonlinear
association between SBP measured in United Kingdom populations
with type 2 diabetes and the adjusted predicted inpatient cost for
CVD hospitalization over 2 years of follow up, after accounting for
the risk of CVD hospitalization both in the main and replication
cohort. Further investigation revealed that SBP <137 mmHg was
associated with stable lowest inpatient cost, and inpatient cost
increased with an increase in SBP >137 mmHg. The peer-support
intervention, especially group intervention combined with 1:1
support, had a significant impact on the association between
inpatient cost for CVD hospitalization and SBP.
Comparison with previous studies
It is well established that SBP is the major determinant of CVD
risk in the population >50 years of age (20). In patients with type 2
diabetes, previous studies have revealed a J-shape relationship
between SBP and CVD event risk; for example, the United Kingdom
Prospective Diabetes Study (21) showed a lowered CVD event rate
with an attained lower blood pressure goal of 144/82 mm Hg. The
International Verapamil SRdTrandolapril (22) and the Avoiding
CVD Events in Combination Therapy in Patients Living with Systolic
Hypertension (23) trials also failed to demonstrate a CVD outcome
benefit at a blood pressure of <130/80 mmHg. We have previously
shown that an SBP between 133 and 141 mmHg was associated
with the lowest risk of CVD hospitalization among patients with
type 2 diabetes (6). However, it was not clear whether this J-shape
relationship exists between SBP and inpatient costs for CVD hos-
pitalization as most studies analyzed health cost/payments that
had a skewed distribution. Ours is the first study among patients
with type 2 diabetes mellitus, following adjustment for the indi-
vidual probability of being hospitalized, and we have now shown a
“hockey-stick”-shaped relationship between SBP and CVD inpatient
payment. This finding suggests that CVD inpatient payments are
stable for SBP below 133 to 141 mmHg and linearly increase above
this range. This in turn supports an SBP target between 133 and 141
mmHg to minimize future risk of CVD hospitalization and associ-
ated inpatient payments.
Although we have shown that CVD hospital payments increase
with a baseline SBP above 133 to 144 mmHg, this was not observed
in the 2-year posttrial period for RAPSID intervention participants.
In RAPSID, peer group support was associated with a significant
reduction in SBP after 8- to 12-month follow up from baseline and
we speculate that it was this lower SBP that was responsible for this
finding. Hospitalization was shown to be reduced in Hong Kong
with peer support among those who had high diabetes distress
Figure 1. Adjusted association between baseline systolic blood pressure and predicted inpatient cost due to CV disease hospitalization in the main cohort and replication cohort. CV,
cardiovascular.
Figure 2. Adjusted association between baseline systolic blood pressure and predicted inpatient cost due to CV disease hospitalization in groups of the replication cohort. CV,
cardiovascular.
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(24). We have not been able to elucidate the mechanism behind the
lower SBP in RAPSID and have excluded a greater effect among
those with high diabetes distress and medication adherence. There
was also no evidence of changes in lifestyle as measured by ques-
tionnaires, or crudely by body weight (a small reduction in waist
circumference was found in the per-protocol analyses). The current
finding of reduced CVD hospitalization costs does provide some
validity that the lower SBP described was not simply due to chance.
The data suggest that the peer-support intervention was asso-
ciated with a reduced inpatient payment; however, in the 2-year
post-trial follow up among patients in the combined intervention
group, CVD inpatient payment did not increase along with the
increase of SBP, especially beyond 133 to 141 mmHg. The slight
reduction in CVD inpatient payment suggests that patients whose
SBP was beyond 133 to 141 mmHg were less likely to trigger the
CVD hospitalization, with this primarily due to the combined peer-
support intervention. It could be that patients in the combined
intervention group adhered to a healthy lifestyle in the post-trial
follow up, which could have impacted patients’ obesity status and
then SBP, as observed in the trial follow up. However, no post-trial
obesity measurement was done to validate this hypothesis. In the
trial follow up the SBP reduction could not be explained by
increasedmedication adherence, as this was previously found to be
unchanged (10). It is unclear whether the antihypertensive treat-
ment adherence pattern was modified in the post-trial follow-up
restricted by the post-trial information on the medication
adherence.
Strength and limitations
One strength of our analysis is that the association between SBP
and CVD inpatient payment was examined in 2 independent
cohorts. Another strength is the minimal information bias, with the
outcome used, recorded inpatient payments, having been fully
recorded by the CCG (14). In particular, as these are payment
details, both NHS hospitals and private hospital admissions were
able to be included. There would have been some loss for patients
where no component of care was paid for by the CCG.
Some limitations must also be considered in the interpretation
of our findings. Unlike pharmaceutical interventions, where
adherence can be assessed using pill counters, it is difficult to
evaluate the magnitude of peer-support intervention on an indi-
vidual level, and, although we did record attendance and telephone
calls, we did not assess engagement. The payment/savings from
similar peer-support interventions should be further investigated
in other post-trial observation studies. Another limitation is the
inconsistent blood pressure measurement approaches between
those used in primary care (main cohort) and those used in the trial
(replication cohort) in terms of attended vs unattended, stan-
dardized protocol vs usual measurement and automated vs mer-
cury sphygmomanometer. A final limitation of our study is that we
obtained information on the activities of the participants after the
trial was completed. All participants were sent the results, and we
are aware that some intervention (e.g. peer-support groups)
continued, including support from the Diabetes UK Type 2 Together
program (11).
In conclusion, to our knowledge, this study is the first to
examine the prospective association between SBP and 2-year
estimated CVD inpatient payments. A “hockey-stick” relationship
between SBP and 2-year estimated CVD inpatient payment was
identified in 2 independent cohorts, with a consistent threshold at
133 to 141 mmHg and a linearly increasing payment beyond the
threshold. An alteration in this relationship after a combined peer-
support intervention (group and 1:1 interventions) is suggested by
the lack of increase in estimated CVD payment. Our findings sug-
gest that, among people with type 2 diabetes, blood pressure
management should target an SBP of 133 to 141 mmHg. Integration
of this threshold into clinical practice could lower both individual
risk of and associated payments for CVD hospitalization.
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Supplementary Figure 1. Adjusted association between baseline systolic blood pressure and predicted inpatient cost due to cardiovascular disease hospitalization in those
receiving 1:1 support intervention (1:1 and combined intervention) and the others (control and group intervention). CV, cardiovascular.
Supplementary Table 2
Distribution of baseline characteristics among patients with and without inpatient
cost due to CVD hospitalization
People with
payment
People with zero
payment
P value
N 769 5,054
Age, years 71.411.8 64.016.0 <0.0001
Female, n (%) 282 (36.6) 2,084 (41.2) <0.0001
Systolic blood pressure,
mmHg
138.316.9 135.216.2 <0.0001
Diastolic blood pressure,
mmHg
75.310.0 76.49.9 <0.0001
Total cholesterol, mmol/L 4.31.1 4.31.2 0.0356
High-density lipoprotein,
mmol/L
1.20.4 1.30.5 <0.0001
Low-density lipoprotein,
mmol/L
2.30.9 2.51.0 <0.0001
Body mass index, kg/m2 31.96.9 30.86.8 <0.0001
A1C, mmol/mol 61.716.7 60.716.6 <0.0001
Lipid-lowering treatment,
n (%)
141 (18.3) 1,596 (31.6) <0.0001
A1C, glycated hemoglobin; CVD, cardiovascular disease.
Supplementary Table 1
Distribution of baseline characteristics and inpatient cost due to CVD hospitalization
in the study cohorts
Median cost
(interquartile range) among people
with nonzero payment, £
People with zero
payment, N (%)
Main cohort 4,348.35 (1,623.50‒8,766.75) 4,116 (87.5%)
Replication
cohort, overall
2,430.72 (793.06‒4,026.20) 938 (83.7%)
Replication
cohort, control
2,419.60 (1,006.91‒4,387.66) 232 (79.7%)
Replication
cohort, group
2,489.40 (770.69‒4,387.66) 216 (82.8%)
Replication
cohort, 1:1
1,963.56 (714.93‒4,032.55) 246 (85.4%%)
Replication
cohort,
combined
2,436.00 (885.19‒3,473.12) 244 (86.8%)
CVD, cardiovascular disease.
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